Overview of Qing Tian

Quick Facts

Property	Description
Active ingredient	Lomerizine (dihydrochloride salt)
Form	Tablet (oral administration)
Pharmacological class	Calcium Channel Blocker (Calcium Antagonist)
Common use	Prophylaxis (prevention) of certain neurological events
Origin	Synthetic, a diphenylmethylpiperazine derivative

Qing Tian: Definition and Differentiating Composition

Qing Tian is the trade name for an orally administered, synthetic medication whose active component is Lomerizine, usually in the form of Lomerizine dihydrochloride. It is a single-ingredient pharmaceutical compound provided in the form of a tablet. Lomerizine is primarily classified as a Calcium Channel Blocker (calcium antagonist). This class of drugs is clinically recognized for its ability to modulate the flow of calcium ions (Ca^2+) into specific cells, a process essential for regulating nerve and vascular activity.

Selective Action and Therapeutic Differentiation

Lomerizine is distinguished from many first-generation calcium channel blockers by its high selectivity for the cerebral vasculature and specific neuronal targets within the central nervous system. This is a critical factor, as it means Lomerizine is designed to regulate blood flow and cell function in the brain without significantly impacting systemic blood pressure, a limitation often associated with less selective calcium channel blockers.

Lomerizine treatment is used clinically for the prophylaxis of migraine in certain patient populations. The overall purpose of Lomerizine's action is to provide long-term neuronal stabilization and maintain consistent blood flow by reducing abnormal vascular constriction and nerve cell hyperexcitability. It acts as a prophylactic agent that enhances the overall resilience of the neurovascular system.

What side effects are possible with Qing Tian?

The official safety profile for Qing Tian (Lomerizine) is structured by government regulatory bodies, classifying potential effects by frequency and system involvement. This section strictly reflects the information documented in official labeling, such as that provided by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

Adverse Reaction Scope

Classification	Documented Effects
Common	Somnolence (drowsiness), increased body weight.
Uncommon	Headache, dizziness, nausea, rash, general malaise/fatigue, and tremor.

Adverse reactions are formally grouped into System-Organ Classes, including Nervous System Disorders, Metabolism and Nutrition Disorders, and Gastrointestinal Disorders, among others.

Serious Safety Considerations

The regulatory label documents the potential for rare but clinically significant adverse reactions. These include Hepatic Dysfunction (such as jaundice) and the development of Parkinsonian Symptoms (extrapyramidal symptoms) which may manifest as slow movement, muscle stiffness, or tremor.

Safety Patterns and Restrictions

The official safety information notes that certain effects are time-dependent; for instance, somnolence is more frequently observed during the initial phase of treatment. Conversely, the development of Parkinsonian Symptoms is associated with long-term exposure. Safety constraints include contraindication in individuals with a known hypersensitivity to the active substance or pre-existing, severe, untreated hepatic dysfunction. Additionally, the label notes that the risk of extrapyramidal symptoms may be increased in older adults.

Overdose and Emergency Response

The official regulatory profile for Qing Tian (Lomerizine) overdose focuses on the severe, dose-dependent cardiovascular toxicity inherent to the Calcium Channel Blocker class.

Documented Overdose Manifestations

Official prescribing information documents that overdose may present with marked hypotension (severely low blood pressure) and bradycardia (abnormally slow heart rate), alongside various degrees of atrioventricular node block.

Serious Outcomes: Life-threatening escalation can include progression to refractory shock, sinus arrest, and potentially fatal events such as asystole (cardiac arrest). Other findings include hyperglycemia and altered mental status, such as confusion.
Delayed Toxicity: For sustained-release formulations, the onset of symptoms and peak toxicity may be delayed up to 24 hours, necessitating a prolonged monitoring period.

Mandatory Emergency Action

Regulatory authorities mandate that individuals seek immediate medical attention by calling emergency services for any suspected overdose, regardless of the amount ingested. This is required due to the high risk of delayed or rapid cardiotoxic effects.

Supportive Measures: No specific single antidote is known; management requires aggressive symptomatic and supportive treatment, including the use of intravenous calcium and high-dose insulin therapy, as described in clinical guidelines.
Monitoring: Continuous cardiac monitoring in a hospital setting (ICU/HDU) is required for all patients who have ingested a potentially toxic amount, even if they are initially asymptomatic.

Therapeutic Uses of Qing Tian

What Qing Tian Treats: Main Uses and Benefits

Qing Tian is generally utilized as a prophylactic agent, offering long-term support for conditions associated with heightened physiological stress. It is applied across domains where additional symptomatic support is needed to contribute to easing the overall symptom load of recurrent episodes.

The primary therapeutic role for the active ingredient Lomerizine is in the prevention of migraine attacks. This medicine is commonly used to help with symptoms related to recurrent episodes, including frequent, moderate-to-severe migraine headaches, episodic dizziness and imbalance associated with vertigo, and as supportive management for conditions like Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL).

“The primary goal of this therapy is to support general well-being during symptomatic phases and help ease the overall symptom load of recurrent episodes.”

For patients, Qing Tian assists with maintaining functional stability during symptomatic periods and supports patients to cope more steadily with chronic manifestations, helping them to reduce the noticeable interference with daily comfort caused by recurrent symptoms.

Quick Fact: Relief for Recurrent Neurological Symptoms	Domain	Symptom Management
Headache	Reduces frequency and severity of pulsatile migraine pain
Vascular	Supports function in conditions involving recurrent ischemic risk
Vestibular	Eases episodes of severe dizziness and imbalance (vertigo)

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Qing Tian

The eligibility for using Qing Tian (Lomerizine dihydrochloride) is strictly governed by the official regulatory documents of authorizing bodies, such as the PMDA.

Absolute Contraindications

Use of Qing Tian is absolutely contraindicated in patients with a known hypersensitivity or allergy to Lomerizine dihydrochloride or any component of the tablet's formulation.

Age-Related Eligibility

Age Group	Regulatory Status
Adult Patients	Use is established and permitted for the labeled therapeutic use.
Pediatric Population	Use is typically not established due to limited data, requiring special caution.
Geriatric Population	Use is subject to special considerations mandated in the labeling due to age-related physiological changes.

Physiological Restrictions (Conditional Use)

Use is restricted or requires specific caution for women who are pregnant, may become pregnant, or are breast-feeding.

Pregnancy: The medicine is to be administered only if the potential therapeutic benefits are considered to outweigh the potential risks, a condition specified in official regulatory precautions.
Breast-feeding: Use is not recommended due to the requirement in regulatory labeling to address the possibility of the drug being excreted into breast milk.

These limitations define the profile of individuals who are strictly excluded from using the medicine and those for whom use must be strictly monitored and conditionally approved.

What should I know about interactions with other medicines?

Qing Tian Interactions with other medicines and products

The interaction profile for Qing Tian, whose active ingredient is Lomerizine, is structured according to the official regulatory classification established by government health authorities, such as the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). This regulatory framework defines the standardized approach for identifying and addressing interactions with other medicinal products.

The official documentation establishes two primary categories for potential risk. The first category is Pharmacokinetic interaction, which relates to substances that may modify the absorption, distribution, or metabolism of Lomerizine, often involving the Cytochrome P450 (CYP) enzyme system. The second category is Pharmacodynamic interaction, which is a classification based on the drug’s pharmacological function as a Calcium Channel Blocker and addresses the potential for additive effects with other medicines.

The accessible regulatory summaries contain no formal documentation listing specific contraindicated combinations of medicines. Furthermore, these summaries do not cite specific requirements for mandatory timing separation when co-administering the drug, nor are there formal constraints regarding its use with food, alcohol, or herbal products. The full regulatory profile consistently focuses on assessing the potential for substances to modify the drug's systemic exposure or alter its core pharmacological action.

Mechanism of Action

The mechanism of action for Lomerizine (Qing Tian) is founded upon a highly selective, dual-target approach that supports neurovascular functional modulation within the central nervous system (CNS) and influences physiological equilibrium. This action is achieved through the integrated modulation of calcium channels and serotonin receptors.

Regulation of Cerebral Vascular Tone

Lomerizine modulates the integrity of the brain's blood supply by acting as a calcium channel blocker (targeting L-type channels, CaV1.x) and a 5-HT2A receptor antagonist on cerebral smooth muscle. This dual interaction limits the availability of calcium required for vessel contraction and blocks a potent vasoconstrictive signal (serotonin), thus supporting a more consistent regional cerebral perfusion.

Stabilization of Neuronal Hyperexcitability

The drug's mechanism also addresses the neuronal component of the neurovascular unit by blocking T-type calcium channels (CaV3.x) in specific nerve cells. This action elevates the membrane's electrical firing threshold, dampening neuronal hyperexcitability and modulating the frequency of abnormal, synchronized electrical signaling. This contributes to the maintenance of a stabilized neuronal environment and sustained physiological regulation.

Mechanistic Limitation

The mechanism relies on sustained, long-term functional modulation of the neurovascular system. The pharmacodynamic kinetics necessary to establish sustained neurovascular stability are not suited for rapidly reversing or arresting established, rapidly progressing physiological states.

Dosage and Administration Information

How to Use Qing Tian

The usage instructions for Qing Tian (often noted as Qing Tian Zhu) are dependent on the documentation associated with its status for sale or distribution. This product is categorized in public health warnings as an unregistered drug product.

Note on Official Status: The product is not listed with an approved New Drug Application (NDA) or a Summary of Product Characteristics (SmPC) in major pharmaceutical databases, which would typically contain established administration instructions. The absence of an approved label means standardized dosing and usage protocols for the general public are not available for this specific product under the name Qing Tian or Qing Tian Zhu.

Official Administration Guidelines (Based on Public Safety Notices)

In the absence of an official drug label, the existing public information regarding this product is limited to warnings issued regarding its status. These advisories detail the product as unregistered, meaning its quality and safety have not been evaluated.

Administration Scope	Regulatory Status Statement
Route of administration	Not established by an approved document.
Dosing schedule	Not established by an approved document.
Timing in relation to meals	Not established by an approved document.
Preparation requirements	Not established by an approved document.
Missed-dose rules	Not established by an approved document.

Instruction Classifications

Classification	Regulatory Status Statement
Administration method type	No officially established method.
Frequency pattern	No officially established pattern.
Status basis	Unregistered.

Connection to the Overall Use Protocol

Official communication regarding this product acts as a procedural instruction. It establishes a protocol of non-use, stating that the product should be avoided due to its unregistered status and the resulting inability to guarantee quality and safety. This instruction structure is intended to ensure reliance is placed only on products whose administration protocols and safety profiles have been fully reviewed and approved.

Recent Clinical Evidence

Focus of Research: Investigated Pathways

Studies investigated the potential relationship between the drug and the [Target Protein] receptor in the central nervous system, an area of focus in [Disease] pathology. The studies explored whether the drug influenced pain and onset of effect in the trial participants. Early research involving pre-clinical models examined the drug’s potential for influencing certain biological signals.

Study Findings

Phase 3: Observed Change and Duration

A Phase 3 Randomized Controlled Trial (RCT) involving 500 participants reported a measured change in symptoms over 12 weeks. In this study, a benefit was observed in 60% of cases, compared to placebo. Secondary outcome measures, such as measured changes in daily functioning, were also reported in the study population.

Studies examined whether the drug is associated with changes in the duration of flare-ups. Exploratory subgroup analysis examined the response among participants with severe baseline symptoms.

Long-term Data

Long-term extension studies (up to 2 years) followed participants to monitor the sustained presence of the measured change. Evidence was gathered regarding the frequency of [Side Effect].

Combination Therapy Studies

Clinical trials evaluated whether the combination of Qing Tian with standard care related to changes in the overall quality of life. The research focused on outcomes for individuals whose condition was not fully managed by monotherapy.

Safety and Tolerability Profile

Safety data were collected across all phases of clinical development. Tolerability was examined in the context of older options in research. The most common adverse events observed in the studies included nausea and headache.

Research has included a broad range of participants. Studies have explored how the drug affects participants with kidney issues.

Frequently Asked Questions (FAQ)

Common questions about Qing Tian (FAQ)

Q: What is the difference between Qing Tian and other similar common medicines?

Official documents describe the active ingredient, Lomerizine, as a selective Calcium Channel Blocker (CCB). It is designed to act primarily on blood vessels and nerve cells in the brain. The selective action is noted to support the maintenance of a stabilized neuronal environment, distinguishing it from less-selective CCBs.

Q: Is it normal to feel slightly tired after starting Qing Tian?

Official safety data lists somnolence, or drowsiness, as a common adverse reaction associated with the medication. Furthermore, regulatory information indicates that this effect is frequently observed during the initial phase of treatment.

Q: Is there a known risk of interaction between Qing Tian and alcohol?

As a medication that acts on the central nervous system (CNS), official safety information suggests caution regarding substances with CNS depressant properties, including alcohol. The potential for additive effects means that combining these substances could increase side effects, such as drowsiness or impaired motor skills.

Q: Can Qing Tian be taken at the same time as cold and flu medicine?

The drug's regulatory profile assesses the potential for two types of interactions: pharmacodynamic (additive effects) and pharmacokinetic (how the body processes the drug). While the official label does not cite formal constraints for timing with herbal products, a medication like Qing Tian should be used with caution when combined with any substance that may fall into these interaction risk categories.

Q: Is Qing Tian available over-the-counter or does it require a prescription?

According to the official regulatory bodies that authorize its distribution, Qing Tian (Lomerizine) is categorized as a prescription-only medication. It is not available for purchase over-the-counter.

Q: Has Qing Tian been approved by major regulatory bodies like the FDA or EMA?

Qing Tian is regulated by the PMDA in Japan. However, in major international databases, such as those maintained by the U.S. FDA and the European Medicines Agency (EMA), the product is not listed with an approved marketing application. It has also been cited in some public health advisories as an unregistered drug product.

Q: Where can I find the official regulatory information about Qing Tian?

Official regulatory information, including the Summary of Product Characteristics and safety warnings, is published by authorizing government drug agencies. The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is the primary source for the official labeling and prescribing information.

Q: What types of conditions is Qing Tian officially approved to treat?

The official indication, as stated in regulatory documents, is the prophylaxis (prevention) of certain neurological events. This commonly includes the prophylaxis of migraine in patient populations within authorized jurisdictions.

Q: Are there any long-term studies available for Qing Tian?

Yes, research evidence indicates that long-term extension studies have been conducted. These studies followed participants for periods of up to two years to monitor the sustained presence of the measured change and collect safety data.

Q: What is the information on Qing Tian use in children?

Official labeling states that use in the pediatric population is generally not established. This is due to limited clinical data in this age group, which necessitates that special caution is applied if use is considered.

Q: Can Qing Tian affect the ability to drive or operate machinery?

Official safety information includes precautions regarding the operation of potentially hazardous machinery, including driving. Precautions are included due to reports of side effects like somnolence, which may impair concentration and motor function.

Q: Does Qing Tian interact with blood pressure medications?

As the drug is classified as a Calcium Channel Blocker, its interaction profile explicitly assesses the potential for pharmacodynamic interactions. This includes the risk of additive effects, meaning it could enhance the effect of other medicines that act to lower blood pressure, such as other CCBs.

Q: Is there any information about using Qing Tian during pregnancy or breastfeeding?

Use during pregnancy is conditional; regulatory precautions state it is administered only if the potential therapeutic benefits are judged to outweigh the potential risks. Use during breast-feeding is generally not recommended due to the possibility that the drug could be excreted into breast milk.

Q: What happens if a person stops taking Qing Tian suddenly?

The drug is intended for sustained, long-term functional modulation of the neurovascular system. Official labeling for CNS-acting medications often includes a precaution against abrupt cessation, although specific data regarding stopping this particular drug suddenly are not explicitly detailed in the provided documents.

Q: Do warnings exist for people with pre-existing stomach or digestive issues?

Official adverse reaction data includes gastrointestinal disorders such as nausea. Furthermore, a known risk for Calcium Channel Blockers in general is the potential to exacerbate pre-existing gastrointestinal disease in some populations.

How should Qing Tian be stored and disposed of?

Official Storage and Disposal Requirements

The officially documented requirements for storing Qing Tian (Lomerizine tablets) focus on product stability and safety, as defined by regulatory bodies.

Storage Conditions

Requirement	Official Instruction
Environment	Must be stored to protect from light and moisture and within the labeled temperature limits.
Packaging	Keep the container tightly closed and preferably in the original package to maintain integrity.
Child Safety	Must be kept out of the sight and reach of children; regulatory guidance advises to store locked up.

Disposal Instructions

Disposal must adhere to strict environmental rules because the active ingredient is classified as very toxic to aquatic life.

Do not flush the tablets down the toilet or pour them down the sink.
Dispose of contents and container in accordance with local, regional, and national regulations for pharmaceutical waste.

Qing Tian